BioMedPartners Close Third Healthcare Venture Fund at CHF 100 Million

01.03.2018 15:22

Related tags


BioMedPartners AG, based in Basel, announced today the final closing of BioMedInvest III, their third equity venture capital fund. BioMedInvest III is a healthcare venture capital fund which will invest in 12 to 15 private early-to-mid-stage companies in Switzerland, Germany and neighboring countries of the European Union. 

“We are delighted that the continued success of BioMedInvest convinced many of the major investors of the previous funds to commit also to BioMedInvest III. Among these are the European Investment Fund (EIF) on behalf of the ERP-EIF Dachfonds as cornerstone investor and the Berner Kantonalbank, BEKB. In addition we could gain the Basellandschaftliche Kantonalbank, BLKB, and several important new private persons as new investors,” says Dr. Markus Hosang, General Partner at BioMedPartners.

Markus Hosang mentions several reasons why well-known investors entrusted their money to the third BioMedInvest fund. The firm’s track record plays an important role: “We have been active in the industry for 15 years, and during this time we have generated a financial return for our investors, which builds trust,” says Hosang.

This is all the more true as BioMedPartners has always remained true to its strategy and has not relied on fashionable themes or markets. The third fund also invests primarily in start-ups that focus on drug development. The firm benefits from the fact that it can count on the extensive pharma R&D experience within the team, and has been intensively involved in a clearly defined market for years and now knows it extremely well, including the active start-ups

Last but not least, Hosang points to the benefits for patients and the economic impact of companies financed by BioMedInvest. “Several medications invented by our companies are now on the market, such as the cancer drug Gazyva, originally invented by Glycart [bought in 2005 by Roche] and an Ebola vaccine from Okairos [purchased by GlaxoSmithKline in 2013].”

With its new fund, BioMedPartners will be able to continue its successful strategy of investing in innovative biopharmaceutical, medical device and diagnostics companies. “We focus on translating the accelerating progress in science into the development of competitive products that address important patient needs” says Dr. Andreas Wallnöfer, General Partner at BioMedPartners. “We select and invest into companies with strong and competent leadership since people are at the core to realize business success and value for patients” adds Stefan Fäs, CFO at BioMedPartners.

With its volume of CHF 100 million, BioMedInvest III will invest in 12 – 15 private companies, supporting them not only by providing funds, but also by taking an active role on the boards of its portfolio companies and by providing senior business expertise and access to its extensive network of industry experts and scientific leaders.

After its first closing in February 2017, the fund has already made its first three investments. These are: Cardior Pharmaceuticals, a German biotech company that develops new therapeutics for the treatment and prevention of heart disease, Amal Therapeutics, a Geneva-based company that pursues novel therapeutic vaccines for the immune-therapy of cancers and Allecra Therapeutics SAS, a late-stage antibiotics company based in the Basel area.

“We are proud of having established BioMedPartners as a leading venture group and early-stage life science investor in Europe over the last fifteen years since its inception. The successful closing of our third equity venture fund is also a major milestone for the future growth of the Life Science Cluster in Switzerland”, adds Thomas Möller, General Partner at BioMedPartners.

About BioMedPartners
Based in Basel, BioMedPartners is a leading independent European venture capital firm, providing private equity to early- to mid-stage life sciences companies, frequently acting as lead- or co-lead investor. Since its foundation in 2003, BioMedPartners has, out of its BioMedInvest funds, invested in 55 highly innovative companies, of which 19 have already either successfully been acquired by leading biopharma players (including Glycart Biotechnologies, ESBATech, Okairos, SuppreMol and Symetis) or done an IPO (including Arpida, Curetis and Santhera). With now more than CHF 350 million in committed capital and a strong team of experienced industry experts BioMedPartners has established itself as one of the leading early-stage human healthcare investors in Europe.


Please login or
register to comment

Please login or sign up to comment. Commenting guidelines

Please login or
register to use the
bookmark feature

Related tags

Read more about




By continuing to use this website you agree with our TERMS AND CONDITIONS